A market research firm says the market for skin-worn health sensors will more than triple in five years. Wissen Research’s new report, announced October 13, puts the global sensor patch market at $7.9 billion in 2026 and projects it will reach $28.9 billion by 2031. That works out to a compound annual growth rate (CAGR) of 29.6%.

It’s a big number. It is also a single firm’s forecast, issued in a release built to sell the report, with no methodology attached. Anyone tracking Abbott, Dexcom, or iRhythm should hold it up against what those companies actually project for themselves.

What the Report Claims

In Wissen’s definition, sensor patches are adhesive devices worn on the skin that track signals like glucose, heart rhythm, or temperature, then send the data to a phone, cloud platform, or clinician.

Two uses are commercially mature. Continuous glucose monitoring (CGM) tracks blood sugar around the clock through a tiny filament under the skin. Ambulatory cardiac monitoring records the heart’s electrical activity for days or weeks outside a hospital.

According to the report, amperometric sensors held the largest technology share in 2025. These measure the electrical current from a chemical reaction, and most CGMs use them. Body-worn patches led by wearable type. North America led by region, while Asia Pacific is described as the fastest growing.

None of those shares comes with a dollar figure or a percentage in the release.

What the Release Leaves Out

There is no sample size. No explanation of how the $7.9 billion baseline was built. No list of which product revenues count as sensor patch revenue and which don’t. The release instead points readers to a free sample request and a paid version of the full report.

Those gaps matter because the category looks loose. The release’s own list of key players includes Senseonics (Nasdaq: SENS), whose Eversense 365 is a sensor implanted under the skin for up to a year, not an adhesive patch. It also names Philips and GE HealthCare, whose monitoring businesses reach well beyond wearables.

A Forecast That Outruns the Leaders

The most useful check is the industry’s own guidance. Dexcom (Nasdaq: DXCM) reported 2025 revenue of $4.662 billion, up 16%. For 2026, it has guided to $5.16 billion to $5.25 billion, or roughly 11% to 13% growth.

iRhythm (Nasdaq: IRTC), maker of the Zio heart monitor, grew 2025 revenue 26.2% to $747.1 million. Its 2026 guidance, issued before its latest acquisition, calls for 16% to 18% growth.

Neither comes close to 29.6% a year. For the whole market to compound that fast while two of its best-known pure-play companies grow more slowly, much of the growth would have to come from products that are early-stage today, such as sweat sensors or multi-signal patches. The release itself concedes that many of those systems are still being validated.

Then there’s scale. Abbott’s (NYSE: ABT) CGM sales alone topped $7.5 billion in 2025, according to independent reporting on its results. Add Dexcom’s $4.662 billion and two companies booked more than $12 billion last year, well above Wissen’s $7.9 billion estimate for the entire 2026 market. By BioTech Stocks Daily’s arithmetic, that suggests the report counts only part of these sales or draws the market more narrowly than its headline implies. The release doesn’t say which.

Rival firms don’t agree, either. MarketsandMarkets projected growth from $6.32 billion in 2025 to $23.91 billion by 2030, a 30.5% CAGR. Market Glass, formerly Global Industry Analysts, put sensor patches at $3.5 billion in 2023, rising to $36.3 billion by 2030. A separate Market Glass report on the broader wearable patch market forecast just 10.5% annual growth. Same sector. Very different answers.

The Real Developments Underneath

Set the forecast aside and the release does point to real events.

In June, the FDA cleared Dexcom’s over-the-counter Stelo biosensor for people aged 2 and older who don’t use insulin, which the agency called the first OTC CGM cleared for children. Kids must use it under adult supervision.

In May, Abbott won a CE Mark in Europe for Libre Duo and Libre Duo 10 Day, which it describes as the world’s first dual glucose-ketone sensors. Ketones are acids that can build to dangerous levels in diabetic ketoacidosis. Libre Duo is not cleared or sold in the U.S.

A Dated Deal, and Some Stale Numbers

The release says iRhythm agreed to acquire private wearable maker VitalConnect in April 2026. Public records say otherwise. The deal, valued at about $287.5 million in cash and stock, was announced in August alongside iRhythm’s second-quarter results. It closed on October 5, more than a week before Wissen’s release still described it as pending.

Other figures have aged, too. The release cites Abbott’s 2024 diabetes care revenue rather than its 2025 results, which have been public since early this year. And Dexcom’s 3.5 million customer count, quoted in the release, excludes Stelo users, per Dexcom’s annual report.

None of these errors is large on its own. Together, they are a reason to read the report’s other figures with care.

What to Watch Instead

The trend underneath is real. Glucose and heart-rhythm patches are large, growing businesses with established FDA pathways. But the 29.6% figure is one firm’s projection, built on undisclosed methods, and it sits well above what the sector’s leaders expect for themselves.

iRhythm plans to update its 2026 guidance, now including VitalConnect, on its November 5 earnings call. That number, plus the next quarterly reports from Dexcom and Abbott, will say more about this market’s real pace than any five-year forecast.

Sources

• Wissen Research: Sensor Patch Market to Reach US$ 28.9 Bn by 2031, Growing at 29.6% CAGR as Continuous Glucose and Cardiac Monitoring Expand, PRNewswire, October 13, 2026. Primary source release.
• Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results, cited for Dexcom’s 2025 revenue and 2026 revenue guidance.
• Dexcom 2025 Annual Report (SEC EDGAR), cited for the 3.5 million user figure excluding Stelo, a qualifier the Wissen release omitted.
• iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results, cited for iRhythm’s 2025 revenue and 2026 growth guidance.
• HIT Consultant: iRhythm to Acquire VitalConnect for $287.5M, cited for the August 2026 announcement timing and deal structure, which conflict with the release’s April 2026 date.
• iRhythm Completes Acquisition of VitalConnect (Form 8-K exhibit, SEC EDGAR), cited for the October 5, 2026 closing and the planned November 5 guidance update.
• Abbott Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for People With Diabetes, cited for Libre Duo’s CE Mark, wear periods, and lack of U.S. clearance.
• FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children, cited for the June 12, 2026 Stelo pediatric clearance and its conditions.
• Zacks: Reasons to Retain Abbott Stock in Your Portfolio Now, cited for Abbott’s 2025 CGM sales exceeding $7.5 billion.
• MarketsandMarkets: Sensor Patch Market Worth $23.91 Billion by 2030, cited as a competing market estimate.
• Market Glass: Global Sensor Patches Market and Market Glass: Global Wearable Patch Market (via GII), cited as competing market estimates.
• Senseonics Holdings (SENS) Quote, cited to confirm Senseonics’ current Nasdaq listing, which the release did not provide.

Editorial Disclosure

This article is based on a press release issued by Wissen Research LLC, a market research firm, on October 13, 2026, promoting a paid market research report. The release is the firm’s own commercial communication; its market-size and growth figures are projections attributed to Wissen Research and are not independently verified by BioTech Stocks Daily. Company financial results, regulatory actions, deal dates, and competing market estimates cited above were drawn from company filings and releases, the FDA, and independent reporting, since the original release did not address or accurately reflect them. Securities discussed: Abbott Laboratories (NYSE: ABT), DexCom, Inc. (Nasdaq: DXCM), iRhythm Holdings, Inc. (Nasdaq: IRTC), and Senseonics Holdings, Inc. (Nasdaq: SENS). BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Wissen Research, Abbott, Dexcom, iRhythm, Senseonics, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding future market size, growth rates, revenue guidance, product launches, regulatory clearances, and acquisition benefits are forward-looking statements. They involve substantial risks and uncertainties; actual results may differ materially. Medical device and diagnostics investments carry significant financial risk, including competitive, reimbursement, and regulatory risk, which can result in the loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and caregivers should consult appropriate healthcare professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.